Q-omics provides the consensus-scored ARMCX4 profile across patient tissues and cancer cell-line models. ARMCX4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ARMCX4 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, ARMCX4 RNA expression shows 21,054 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, THCA, and UVM as cancer lineages where ARMCX4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARMCX4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARMCX4 survival associations across molecular data types. ARMCX4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARMCX4 RNA expression–survival associations across cancer types. High ARMCX4 expression shows unfavorable associations in UVM, but favorable associations in ACC, HNSC, LGG, PAAD and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ARMCX4 RNA expression.
This table summarizes ARMCX4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ARMCX4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARMCX4 shows lower tumor expression in THCA, UCEC, BRCA, LUAD and BLCA and higher tumor expression in CHOL. The THCA box plot shows higher ARMCX4 RNA expression in normal versus tumor tissue (log2 FC = −0.456, t-test p < 0.001).
This table shows molecular features associated with ARMCX4 in patient tissues and cancer cell lines. In patient samples, ARMCX4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARMCX4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
